CRT 2026

Panel Discussion | BRS Biodegradable Polymers Bioadaptors | Is There a Future for the Technology?

Moderator(s)

• 

  Michael H. Joner, MD

  Associate Professor Interventional Cardiology
  Deutsches Herzzentrum Muenchen
  Munich, Bayern, Germany

  Disclosure(s): QmedConsulting: Consulting Fees (e.g., advisory boards) (Ongoing)
• 

  Yoshinobu Onuma, MD, PhD

  Professor of Interventional Cardiology
  University of Galway
  Galway, Galway, Ireland

  Disclosure(s): No financial relationships to disclose

Panel Discussant(s)

• 

  Alexandre A. Abizaid, MD, PhD

  Full Professor of Cardiology; Director of Invasive Cardiology
  Incor
  SÃO PAULO, Sao Paulo, Brazil

  Disclosure(s): No financial relationships to disclose
• 

  Robert A. Byrne, MD, BCh, PhD

  Director of Cardiology
  Mater Private Hospital, RCSI University of Medicine and Health Sciences, Dublin, Ireland
  Dublin, Ireland

  Disclosure(s): No financial relationships to disclose
• 

  Andrew Farb, MD

  Chief Medical Officer, Office of Cardiovascular Devices
  U.S. Food and Drug Administration
  Silver Spring, Maryland, United States

  Disclosure information not submitted.
• JK

  Jenny Katsnelson

  Disclosure information not submitted.
• 

  Sahil A. Parikh, MD, FSCAI

  Associate Professor of Medicine
  Columbia University Irving Medical Center
  New York, New York, United States

  Disclosure(s): Abbott: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Advanced NanoTherapies: Stock Options [in privately held companies] (Ongoing); AVS: Grant/Research Support (Ongoing); Boston Scientific: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Cagent Vascular: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Concept Medical: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Encompass vascular: Stock Options [in privately held companies] (Ongoing); Fastwave: Grant/Research Support (Ongoing); Inari/Stryker: Consulting Fees (e.g., advisory boards) (Ongoing); Medinol: Grant/Research Support (Ongoing); Penumbra: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Philips: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); R3 Vascular: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Shockwave: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Terumo: Consulting Fees (e.g., advisory boards) (Ongoing)
• 

  Ruben Yannick Gerold Tijssen, MD, PhD

  MD, PhD
  St. Antonius Ziekenhuis Nieuwegein, the Netherlands
  Naarden, Noord-Holland, Netherlands

  Disclosure(s): No financial relationships to disclose
• 

  Nicolas Foin, MSc, PhD

  Adj Associate Professor
  Duke-NUS / Medinbox
  Brussels, Brussels Hoofdstedelijk Gewest, Belgium

  Disclosure(s): Medinbox: Mandate (Ongoing), Stock-privately held company (Ongoing)